MiMedx Group (NASDAQ:MDXG) Given New $10.00 Price Target at Lake Street Capital

MiMedx Group (NASDAQ:MDXG) had its target price reduced by Lake Street Capital from $12.00 to $10.00 in a report released on Tuesday morning,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Several other equities analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Finally, Mizuho decreased their target price on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, December 17th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.67.

MiMedx Group Price Performance

Shares of MiMedx Group stock opened at $5.39 on Tuesday. The company has a quick ratio of 3.95, a current ratio of 4.41 and a debt-to-equity ratio of 0.07. The company has a market cap of $798.26 million, a PE ratio of 19.96 and a beta of 1.57. The business has a 50 day moving average of $6.70 and a 200 day moving average of $6.90. MiMedx Group has a 52 week low of $5.13 and a 52 week high of $9.36.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.08. The business had revenue of $113.73 million for the quarter, compared to analysts’ expectations of $94.74 million. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. As a group, equities research analysts forecast that MiMedx Group will post 0.3 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Kimberly Maersk-Moller sold 58,300 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total value of $432,586.00. Following the sale, the insider directly owned 236,982 shares of the company’s stock, valued at approximately $1,758,406.44. This represents a 19.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On MiMedx Group

Hedge funds have recently bought and sold shares of the company. Trigran Investments Inc. increased its stake in MiMedx Group by 10.4% during the 2nd quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock valued at $51,266,000 after purchasing an additional 790,901 shares in the last quarter. First Light Asset Management LLC lifted its stake in shares of MiMedx Group by 89.5% in the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock worth $25,498,000 after buying an additional 1,725,458 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of MiMedx Group by 4.3% during the third quarter. Dimensional Fund Advisors LP now owns 2,382,333 shares of the company’s stock valued at $16,628,000 after buying an additional 99,084 shares during the last quarter. Punch & Associates Investment Management Inc. increased its position in shares of MiMedx Group by 1.6% during the third quarter. Punch & Associates Investment Management Inc. now owns 2,005,014 shares of the company’s stock valued at $13,995,000 after acquiring an additional 31,082 shares in the last quarter. Finally, Nantahala Capital Management LLC purchased a new position in MiMedx Group in the 3rd quarter worth approximately $10,237,000. Institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.